- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07581457
Tranexamic Acid in Pediatric Idiopathic Scoliosis Surgery
Efficacy and Safety of Two Intravenous Tranexamic Acid Regimens Versus Placebo in Pediatric Idiopathic Scoliosis Surgery: A Randomized Double-Blind Trial
This study will evaluate whether tranexamic acid (TXA), a medication used to reduce bleeding, is effective and safe in children undergoing surgery for idiopathic scoliosis. Significant blood loss is common during this type of surgery and often requires blood transfusions.
Participants will be randomly assigned to one of three groups: (1) TXA given as an intravenous bolus followed by continuous infusion, (2) TXA given as two intravenous bolus doses, or (3) placebo (saline). Neither the patients nor the medical team will know which treatment is given.
The main goal is to compare how much blood is lost during and after surgery and whether TXA reduces the need for blood transfusions. The study will also assess safety, including the risk of side effects such as seizures or blood clots.
Patients will be followed for up to 30 days after surgery.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Posterior spinal fusion for adolescent idiopathic scoliosis is associated with significant intraoperative blood loss and frequent need for blood transfusion. Tranexamic acid (TXA) is an antifibrinolytic agent that reduces bleeding, but optimal dosing strategies in pediatric scoliosis surgery remain unclear.
This study is a prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of two intravenous TXA regimens compared with placebo in children undergoing surgical correction of idiopathic scoliosis.
Participants aged 10-18 years will be randomly assigned to receive either TXA or placebo during surgery. All patients will undergo standardized anesthesia, regional analgesia, and intraoperative neuromonitoring according to institutional protocols.
The primary objective is to assess the effect of TXA on perioperative blood loss. Secondary objectives include evaluation of transfusion requirements, laboratory parameters, and safety outcomes.
Patients will be followed for 30 days after surgery to assess postoperative outcomes and adverse events.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Malgorzata Reysner, MD PhD
- Número de teléfono: +48 61 831-01-22
- Correo electrónico: mreysner@ump.edu.pl
Copia de seguridad de contactos de estudio
- Nombre: Piotr Janusz, MD PhD
- Correo electrónico: pjanusz@um.edu.pl
Ubicaciones de estudio
-
-
-
Poznan, Polonia, 62-701
- Reclutamiento
- Poznan University of Medical Sciences
-
Contacto:
- Malgorzata Reysner, M.D. Ph.D.
- Número de teléfono: +48 61 873 83 03
- Correo electrónico: mreysner@ump.edu.pl
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age 10 to 18 years
- Diagnosis of idiopathic scoliosis requiring surgical correction (posterior spinal fusion)
- American Society of Anesthesiologists (ASA) physical status I-II
- Written informed consent from parents or legal guardians and assent from the child
Exclusion Criteria:
- Congenital or acquired coagulopathy
- History of thromboembolic disease
- History of seizures or epilepsy
- Known hypersensitivity to tranexamic acid
- Renal insufficiency (estimated glomerular filtration rate < 60 mL/min/1.73 m²)
- Cardiac arrhythmias or cardiovascular disease requiring antiplatelet or anticoagulant therapy
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: TXA Bolus + Infusion
Tranexamic acid administered intravenously as a 15 mg/kg bolus after induction of anesthesia, followed by continuous infusion at 1 mg/kg/h until the end of surgery. Maximum total dose not exceeding 2 g. All patients receive standardized anesthesia (TIVA with propofol and remifentanil), erector spinae plane block, and intraoperative neuromonitoring. |
Tranexamic acid administered intravenously as a 15 mg/kg bolus after induction of anesthesia, followed by continuous infusion at 1 mg/kg/h until the end of surgery.
Otros nombres:
|
|
Comparador de placebos: Placebo
0.9% sodium chloride (saline) administered intravenously in the same volumes and timing as the active comparator groups (bolus and infusion). All patients receive standardized anesthesia (TIVA with propofol and remifentanil), erector spinae plane block, and intraoperative neuromonitoring. |
Intravenous administration of 0.9% sodium chloride solution used as placebo, matched in volume and timing to the active comparator groups.
Otros nombres:
|
|
Experimental: TXA Bolus Only
Tranexamic acid administered intravenously as two bolus doses: 10 mg/kg after induction of anesthesia and 10 mg/kg 120 minutes after surgical incision or at the beginning of rod placement (whichever occurs first). Maximum total dose not exceeding 2 g. All patients receive standardized anesthesia (TIVA with propofol and remifentanil), erector spinae plane block, and intraoperative neuromonitoring. |
Tranexamic acid administered intravenously as two bolus doses: 10 mg/kg after induction of anesthesia and 10 mg/kg 120 minutes after surgical incision or at the beginning of rod placement, whichever occurs first.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Total Blood Loss
Periodo de tiempo: 24 hours postoperatively
|
Total blood loss expressed in ml/kg |
24 hours postoperatively
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Total Volume of Blood Transfusion
Periodo de tiempo: 24 hours postoperatively
|
Total volume of transfused blood products (ml/kg) administered intraoperatively and within the first 24 hours postoperatively. |
24 hours postoperatively
|
|
Hemoglobin Level
Periodo de tiempo: immediately after surgery (0 hours)
|
Hemoglobin concentration measured in g/dL |
immediately after surgery (0 hours)
|
|
Hemoglobin Level
Periodo de tiempo: 24 hours postoperatively
|
Hemoglobin concentration measured in g/dL |
24 hours postoperatively
|
|
Hematocrit Level
Periodo de tiempo: immediately after surgery (0 hours)
|
Hematocrit value (%) |
immediately after surgery (0 hours)
|
|
Hematocrit Level
Periodo de tiempo: 24 hours postoperatively
|
Hematocrit value (%) |
24 hours postoperatively
|
|
D-dimer Level
Periodo de tiempo: 24 hours postoperatively
|
Plasma D-dimer concentration measured in mg/L |
24 hours postoperatively
|
|
Fibrinogen Level
Periodo de tiempo: 24 hours postoperatively
|
Plasma fibrinogen concentration measured in g/L |
24 hours postoperatively
|
|
Prothrombin Time
Periodo de tiempo: 24 hours postoperatively
|
Prothrombin time measured in seconds |
24 hours postoperatively
|
|
Activated Partial Thromboplastin Time
Periodo de tiempo: 24 hours postoperatively
|
Activated partial thromboplastin time measured in seconds |
24 hours postoperatively
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: Małgorzata Reysner, MD PhD, Poznan University of Medical Sciences
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades óseas
- Enfermedades musculoesqueléticas
- Enfermedades de la columna
- Curvaturas de la columna
- Escoliosis
- Químicos orgánicos
- Preparaciones farmacéuticas
- Ácidos carboxílicos
- Químicos inorgánicos
- Compuestos de cloro
- Soluciones cristaloides
- Soluciones isotónicas
- Soluciones
- Ácidos, carbocíclicos
- Ácidos ciclohexanecarboxílicos
- Compuestos de sodio
- Cloruros
- Ácido clorhídrico
- Ácido tranexámico
- Solución salina
- Cloruro de sodio
Otros números de identificación del estudio
- 2/2026
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Individual participant data (IPD) underlying the results reported in this study, after de-identification, will be shared. This includes demographic data, perioperative variables, laboratory results, and outcome measures. Supporting documents such as the study protocol and statistical analysis plan will also be available.
Marco de tiempo para compartir IPD
Data will be available beginning 6 months after publication of the primary results and ending 5 years after publication.
Criterios de acceso compartido de IPD
Data will be shared with researchers who provide a methodologically sound proposal. Proposals should be directed to the principal investigator. Data access will be granted following approval by the study investigators and after signing a data access agreement.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .